%0 Journal Article
%T Biodistribution Study of Intravenously Injected Cetuximab-IRDye700DX in Cynomolgus Macaques.
%A de Boer E
%A Samuel S
%A French DN
%A Warram JM
%A Schoeb TR
%A Rosenthal EL
%A Zinn KR
%J Mol Imaging Biol
%V 18
%N 2
%D Apr 2016
%M 26335283
%F 3.484
%R 10.1007/s11307-015-0892-y
%X <B>OBJECTIVE: </B>The use of receptor-targeted antibodies conjugated to photosensitizers is actively being explored to enhance treatment efficacy. To facilitate clinical testing, we evaluated cetuximab conjugated to IRDye700DX (IR700) in cynomolgus macaques.<BR><B>METHODS: </B>Total IR700 and intact cetuximab-IR700 were measured in 51 tissues at 2 and 14 days after intravenous injection of 40 and 80 mg/kg cetuximab-IR700, respectively, and compared with an unlabeled cetuximab-dosed control group (two each per sex per time point per group).<BR><B>RESULTS: </B>The IR700 retrieved from all tissues at 2 and 14 days after dosing was estimated at 34.9 ± 1.8 and 2.53 ± 0.67% of the total dose, respectively. The tissues with the highest levels of intact cetuximab-IR700 at 2 days after dosing were the blood, lung, and skin. Formalin-fixed paraffin-embedded tissue sections at 2 days after dosing showed the highest IR700 signals in the axillary lymph node, mammary gland, and gall bladder.<BR><B>CONCLUSIONS: </B>Both IR700 and intact cetuximab-IR700 biodistributions were consistent with known epidermal growth factor receptor (EGFR) expression, and changes between 2 and 14 days were consistent with rapid metabolism and excretion of the cetuximab-IR700.